<DOC>
	<DOCNO>NCT02153190</DOCNO>
	<brief_summary>The primary purpose study evaluate Artificial Pancreas 2 month home set Type 1 Diabetic patient</brief_summary>
	<brief_title>Hybrid Artificial Pancreas Home Setting</brief_title>
	<detailed_description>During study , propose assess Artificial Pancreas group Type 1 diabetic patient participate two study period two-month duration insulin pump Continuous Glucose Monitoring ( CGM ) device . During one period , call HYBRID Period , patient use AP model home , dinner wake-up time whereas patient self manage glucose control insulin pump CGM rest day . During control period call OPEN Period , patient self management diabetes insulin pump CGM do time . Overall , increase time spent range use artificial pancreas hybrid period observe reduction hypo hyperglycemia episode .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>1 . Age ≥ 18 et &lt; 70 year old 2 . Having diabetes accord WHO criteria least 6 month , Type 1 diabetes accord ADA criterion 3 . Under basalbolus insulin therapy use external insulin pump least 3 month 4 . BMI &lt; 35 kg/m² 5 . Willing wear CGM device whole duration study , except washout period , combine DiAs platform evening nighttime 2 month 6 . Trained carbohydrate count 7 . HbA1c &gt; 7.5 % &lt; 10 % 8 . If antihypertensive , thyroid , antidepressant lipid lower medication , stability medication least 1 month prior study inclusion 9 . Willing undergo study procedure 10 . Informed consent sign Exclusion criterion : 1 . Pregnancy breast feeding , intention pregnant study duration 2 . Use medication significantly impact glucose metabolism , e.g . steroid 3 . Uncontrolled hypertension rest blood pressure 140/90 mmHg 4 . Patient plan go abroad trial period 5 . Patient expect outofhome even night time ( e.g . shiftworkers , etc . ) 25 % study period 6 . Patient hold nearby party assistance need 7 . Patient severe hypoglycemia include coma , mental confusion and/or convulsion request IV glucose injection glucagon injection last year . 8 . Presence malignant disease , unless consider cure 10 year 9 . History acute cardiovascular event prior year 10 . History diabetic ketoacidosis prior 6 month 11 . Renal insufficiency creatinin &gt; 150 μmol/L 12 . Impairment liver status estimate ASAT/ALAT plasma level &gt; 2x upper limit normal value 13 . Impaired cognitive psychological ability may result defective adherence study condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Type 1 Diabetes ,</keyword>
	<keyword>T1DM ,</keyword>
	<keyword>Artificial Pancreas</keyword>
</DOC>